Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
This is a multi-center evaluation of NGM621 in a randomized, double-masked, sham-controlled
study in participants with Geographic Atrophy secondary to Age-related Macular Degeneration.
Phase
Phase 2
Funding Agency/Sponsor
Industry
Disease
Retina
Enrollment Eligibility
Inclusion Criteria:
- Male or female (non-pregnant, non-lactating) subjects ≥ 55 years
- Standard luminance BCVA score of 34 letters or better using ETDRS charts at the
starting distance of 4 meters (approximately 20/200 Snellen equivalent or better) in
study eye
- Clinical diagnosis of GA secondary to AMD:
1. Total GA area must be ≥ 2.5 and ≤ 17.5 mm²
2. If GA is multifocal, at least one focal lesion must be ≥ 1.25 mm² (0.5 DA), with
the overall area of GA ≥ 2.5 and ≤ 17.5 mm²
3. Well demarcated GA with no anatomical evidence of current or prior CNV in the
study eye
Exclusion Criteria:
Study Eye
- GA secondary to a condition other than AMD in either eye (e.g., monogenetic macular
dystrophies like Stargardt disease, cone rod dystrophy, or toxic maculopathies)
- Any history of or active choroidal neovascularization (CNV)
Both Eyes
- Any history of or active bacterial, viral, fungal, or parasitic infection in either
eye in the 3 months prior to randomization